NBIX — NEUROCRINE BIOSCIENCES INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $164M. Across recent filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in NBIX
How many top investors track NBIX
A small number of top investors own this.
NBIX Ownership Composition
How NEUROCRINE BIOSCIENCES INC is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting NBIX
- Izzy EnglanderMar 31, 2026Millennium ManagementShares1.2MValue$164.3M% Portfolio0.07%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares148.1KValue$19.5M% Portfolio0.09%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares88.2KValue$11.6M% Portfolio0.00%
Recent activity
- Sold$0(-100.00%)May 15, 2026
- Reduced$19.5M(-1.23%)May 15, 2026
- New$16.5KFeb 17, 2026
- Increased$21.3K(551.05%)Feb 13, 2026
- New$3.2KNov 13, 2025
Frequently asked questions
- How many institutional investors hold NBIX?
- 3 tracked institutional investors disclosed a position in NBIX (NEUROCRINE BIOSCIENCES INC) in their most recent 13F filing.
- Who is the largest institutional holder of NBIX?
- Izzy Englander, Millennium Management, holds the largest disclosed position in NBIX, valued at $164M.
- Did institutional ownership of NBIX increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 1 fully exited NBIX.
- Where does this NBIX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.